I would think this could also help in getting potential patients lined up for post approval treatment. Presumably, patients will have better outcomes if they start therapy earlier even if the disease progression is just slowed or stopped, and not reversed.
<<<Tremendous advances are being made in FAP research, said Natacha T. Pires, M.B.B.S., Director, Medical and Public Affairs of The Neuropathy Association. This free screening program offered by Alnylam gives patients and their physicians access to laboratory testing for genetic mutations known to be associated with this serious, life-threatening disease. This screening is expected to help enable earlier diagnosis and enhance a patients knowledge of the disorder and how it might affect them and their family members. It will also allow them to initiate discussions with their healthcare provider about their care, and potentially enable them to consider participating in ongoing clinical trials.